Indian pharma companies are focussing on flagship products or mother brands under which they launch various new combinations to ensure robust revenue growth as well as therapy leadership.
An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales.
Sheetal Sapale, vice-president, commercial at Pharmarack, said, Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success.
Indian drug manufacturers are utilizing flagship products or "mother brands" to introduce new combinations and establish leadership in therapy areas, as per research by Pharmarack. For example, USV s anti-diabetes drug Glycomet has bolstered the company s reputation in diabetic therapy and facilitated partnerships with multinational drugmakers for innovative therapies.